Drug Prices

Commentary

Here’s How Trump’s Pick To Lead The FDA Can Supercharge The Agency

The U.S. Senate last week confirmed former Johns Hopkins surgeon and professor Dr. Marty Makary to lead the Food and Drug Administration. During his confirmation hearing, Makary said his goals for the agency were “more cures and meaningful treatments for Americans.” Throughout the hearing, he offered insight on how he ...
Blog

Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field

The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Commentary

Trump is fighting Biden’s drug-price battle — but patients will pay the cost

The Trump administration is experiencing some cognitive dissonance: The new president’s Justice Department is going to bat for former President Joe Biden and his signature legislative accomplishment. Senior Justice officials say they’ll head to court to stick up for Biden’s Inflation Reduction Act and its price controls on prescription drugs. ...
Drug Importation

Sally Pipes – The World’s Medicine Chest

This week, we present a special presentation of our recent webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores ...
Drug Prices

New Brief: ‘Maximum Fair Price’ Policy Would Bring New Costs to Nevada Taxpayers, Put Patient Access to Health Care at Risk

SACRAMENTO – Nevada taxpayers could face millions in new bureaucratic costs and patients will likely see less access to life-saving drugs if state government mandates so-called “Maximum Fair Price” price controls on prescription drugs, finds a new brief released today by the Center for Medical Economics and Innovation at the ...
340B

Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”

Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...
Commentary

Congress Eyes Regulating Drug Ads, It Won’t Mean Lower Prices

“Knowing what something costs before buying it is just common sense.” That’s how Sen. Chuck Grassley, R-Iowa, justified a bill he introduced in January to require drug companies to include a medicine’s list price in their advertisements. Unfortunately, his Drug-price Transparency for Consumers, or DTC, Act — co-sponsored by Sen. ...
Commentary

The World’s Medicine Chest

Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special live ...
Book

Read the new book from Sally Pipes “The World’s Medicine Chest”

Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. <The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special ...
Commentary

Insulin prices are falling due to market forces — no price caps required

California State Sen. Scott Wiener, D-San Francisco, recently introduced legislation that would cap cost-sharing for insulin at $35 a month, regardless of whether a patient has public or private insurance. It’s a popular idea. But it may not be necessary. The cost of insulin has been falling due to market ...
Commentary

Here’s How Trump’s Pick To Lead The FDA Can Supercharge The Agency

The U.S. Senate last week confirmed former Johns Hopkins surgeon and professor Dr. Marty Makary to lead the Food and Drug Administration. During his confirmation hearing, Makary said his goals for the agency were “more cures and meaningful treatments for Americans.” Throughout the hearing, he offered insight on how he ...
Blog

Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field

The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Commentary

Trump is fighting Biden’s drug-price battle — but patients will pay the cost

The Trump administration is experiencing some cognitive dissonance: The new president’s Justice Department is going to bat for former President Joe Biden and his signature legislative accomplishment. Senior Justice officials say they’ll head to court to stick up for Biden’s Inflation Reduction Act and its price controls on prescription drugs. ...
Drug Importation

Sally Pipes – The World’s Medicine Chest

This week, we present a special presentation of our recent webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores ...
Drug Prices

New Brief: ‘Maximum Fair Price’ Policy Would Bring New Costs to Nevada Taxpayers, Put Patient Access to Health Care at Risk

SACRAMENTO – Nevada taxpayers could face millions in new bureaucratic costs and patients will likely see less access to life-saving drugs if state government mandates so-called “Maximum Fair Price” price controls on prescription drugs, finds a new brief released today by the Center for Medical Economics and Innovation at the ...
340B

Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”

Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...
Commentary

Congress Eyes Regulating Drug Ads, It Won’t Mean Lower Prices

“Knowing what something costs before buying it is just common sense.” That’s how Sen. Chuck Grassley, R-Iowa, justified a bill he introduced in January to require drug companies to include a medicine’s list price in their advertisements. Unfortunately, his Drug-price Transparency for Consumers, or DTC, Act — co-sponsored by Sen. ...
Commentary

The World’s Medicine Chest

Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special live ...
Book

Read the new book from Sally Pipes “The World’s Medicine Chest”

Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. <The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special ...
Commentary

Insulin prices are falling due to market forces — no price caps required

California State Sen. Scott Wiener, D-San Francisco, recently introduced legislation that would cap cost-sharing for insulin at $35 a month, regardless of whether a patient has public or private insurance. It’s a popular idea. But it may not be necessary. The cost of insulin has been falling due to market ...
Scroll to Top